F-X Mahon

1.5k citations

26 papers · 682 indexed · h-index 15

Impact in

Hematology top 2%
- Chronic Myeloid Leukemia Treatments
- Acute Myeloid Leukemia Research
- Hematopoietic Stem Cell Transplantation
Genetics top 2%
- Chronic Lymphocytic Leukemia Research

Papers in ⓘ

Hematology 22
- Chronic Myeloid Leukemia Treatments 20
- Acute Myeloid Leukemia Research 3
Genetics 11
- Chronic Lymphocytic Leukemia Research 9
- Myeloproliferative Neoplasms: Diagnosis and Treatment 2

Co-authors: Josy Reiffers (11 shared papers)Françis Belloc (5 shared papers)Jean Ripoche (5 shared papers)Claude Preudhomme (2 shared papers)JV Melo (2 shared papers)Valérie Lagarde (2 shared papers)Catherine Roche‐Lestienne (2 shared papers)Christophe F. Grosset (4 shared papers)
Journals: Leukemia (11 papers)Blood (3 papers)Annals of Oncology (2 papers)British Journal of Haematology (1 paper)Seminars in Hematology (1 paper)
Partner nations: France United States Germany

In The Last Decade

F-X Mahon

26 papers receiving 668 citations

Peers

Countries citing papers authored by F-X Mahon

Since Specialization

Citations

This map shows the geographic impact of F-X Mahon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F-X Mahon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F-X Mahon more than expected).

Fields of papers citing papers by F-X Mahon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by F-X Mahon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F-X Mahon. The network helps show where F-X Mahon may publish in the future.

Co-authors

The 25 scholars most cited alongside F-X Mahon, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with F-X Mahon Line = papers co-authored together F-X Mahon links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 26 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(ϕ)-LMC GROUP) Leukemia ·Franck E. Nicolini, Sélim Corm, Q.H. Le, Nathalie Sorel, Sandrine Hayette, Dominique Bories, Thibaut Leguay, Lydia Roy, Stéphane Giraudier, Michel Tulliez, Thierry Façon, F-X Mahon, JM Cayuela, Philippe Rousselot, M. Michallet, Claude Preudhomme, François Guilhot, Catherine Roche‐Lestienne	2006	154
2	Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs Leukemia ·Aj Tipping, F-X Mahon, G Zafirides, Valérie Lagarde, JM Goldman, JV Melo	2002	67
3	Expression of Flt3-ligand by the endothelial cell Leukemia ·A. Solanilla, Christophe F. Grosset, Claudie Lemercier, M Dupouy, F-X Mahon, Karin Schweitzer, Josy Reiffers, Babette B. Weksler, Jean Ripoche	2000	51
4	PI3K/mTOR pathway inhibitors sensitize chronic myeloid leukemia stem cells to nilotinib and restore the response of progenitors to nilotinib in the presence of stem cell factor Cell Death and Disease ·Kelly Airiau, F-X Mahon, Marina Josselin, Marie Jeanneteau, Françis Belloc	2013	49
5	GILZ inhibits the mTORC2/AKT pathway in BCR-ABL+ cells Oncogene ·Sami Joha, A-L Nugues, Dominique Hétuin, Céline Berthon, Xavier Dezitter, Véronique Dauphin, F-X Mahon, Catherine Roche‐Lestienne, Claude Preudhomme, Bruno Quesnel, Thierry Idziorek	2011	40
6	The stem cell factor–c-KIT pathway must be inhibited to enable apoptosis induced by BCR–ABL inhibitors in chronic myelogenous leukemia cells Leukemia ·Françis Belloc, Kelly Airiau, Marie Jeanneteau, M. Garcia, Estelle Guérin, Éric Lippert, François Moreau‐Gaudry, F-X Mahon	2009	35
7	Corrections to “Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up” Annals of Oncology ·Andreas Hochhaus, Susanne Saußele, Gianantonio Rosti, F-X Mahon, J. Janssen, Henrik Hjorth‐Hansen, Jan Richter, Christian Buske	2018	32
8	Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results Leukemia ·Timothy P. Hughes, Brian Leber, Francisco Cervantes, Nelson Spector, Ricardo Pasqüini, Nelma Clementino, Anthony P. Schwarer, P.E. Dorlhiac‐Llacer, F-X Mahon, Delphine Réa, A. Guerci-Bresler, Suzanne Kamel‐Reid, Israel Bendit, Sandip Acharya, Tara Glynos, Darshan Dalal, Susan Branford, J. H. Lipton	2017	31
9	First-line imatinib mesylate in patients with newly diagnosed accelerated phase-chronic myeloid leukemia Leukemia ·Delphine Réa, Gabriel Étienne, Franck E. Nicolini, Pascale Cony‐Makhoul, Hyacinthe Johnson‐Ansah, Laurence Legros, Françoise Huguet, Michel Tulliez, Martine Gardembas, Krimo Bouabdallah, Philippe Rousselot, JM Cayuela, François Guilhot, F-X Mahon	2012	30
10	Endothelial cell support of hematopoiesis is differentially altered by IL-1 and glucocorticoids Leukemia ·Bożena Jaźwiec, A. Solanilla, Christophe F. Grosset, F-X Mahon, M Dupouy, V Pigeonnier-Lagarde, Françis Belloc, Karin Schweitzer, Josy Reiffers, Jean Ripoche	1998	30
11	Predicting complete cytogenetic response in chronic myelogenous leukemia patients treated with recombinant interferon alpha [letter; comment] Blood ·F-X Mahon, Marion Montastruc, C. Fabères, Josy Reiffers	1994	29
12	In vitro biosynthesis of leukemia inhibitory factor/human interleukin for DA cells by human endothelial cells: differential regulation by interleukin-1 alpha and glucocorticoids Blood ·Christophe F. Grosset, Bożena Jaźwiec, Taupin Jl, Huan Liu, Sophie Richard, F-X Mahon, Josy Reiffers, JF Moreau, Jean Ripoche	1995	28
13	Inhibition of imatinib-mediated apoptosis by the caspase-cleaved form of the tyrosine kinase Lyn in chronic myelogenous leukemia cells Leukemia ·Pascal Gamas, Sandrine Marchetti, Alexandre Puissant, Sébastien Grosso, Arnaud Jacquel, Pascal Colosetti, Jean‐Max Pasquet, F-X Mahon, J.P. Cassuto, Patrick Auberger	2009	20
14	Correction of the enzyme deficit of bone marrow cells in congenital erythropoietic porphyria by retroviral gene transfer PubMed ·François Moreau‐Gaudry, Cécile Barbot, Frédéric Mazurier, F-X Mahon, Josy Reiffers, Cécile Ged, Hubert de Verneuil	1996	17
15	Rapid analysis and efficient selection of human transduced primitive hematopoietic cells using the humanized S65T green fluorescent protein Gene Therapy ·Frédéric Mazurier, François Moreau‐Gaudry, Véronique Maguer‐Satta, Stéphanie Salesse, V Pigeonnier-Lagarde, Cécile Ged, Françis Belloc, Francis Lacombe, F-X Mahon, Josy Reiffers, Hubert de Verneuil	1998	15
16	All-trans retinoic acid potentiates the inhibitory effects of interferon α on chronic myeloid leukemia progenitors in vitro Leukemia ·F-X Mahon, Hikmat Chahine, Cécile Barbot, V. Pigeonnier, Bożena Jaźwiec, Josy Reiffers, Jean Ripoche	1997	13
17	Effect of tyrosine kinase inhibitors on stemness in normal and chronic myeloid leukemia cells Leukemia ·Lucie Charaf, F-X Mahon, Isabelle Lamrissi‐Garcia, Isabelle Moranvillier, François Béliveau, Bruno Cardinaud, Sandrine Dabernat, Hubert de Verneuil, François Moreau‐Gaudry, Aurélie Bedel	2016	11
18	Autologous stem cell transplantation in chronic myeloid leukemia: a single center experience Bone Marrow Transplantation ·Arnaud Pigneux, C. Fabères, JM Boiron, F-X Mahon, Pascale Cony‐Makhoul, Philippe Agapé, A. Lounici, Ph. Bernard, C Bilhou-Nabéra, R. Bouzgarrou, Gérald Marit, Josy Reiffers	1999	8
19	Resistance to daunorubicin-induced apoptosis is not completely reversed in CML blast cells by STI571 Leukemia ·Reza Tabrizi, F-X Mahon, Pascale Cony Makhoul, Valérie Lagarde, Francis Lacombe, P. Berthaud, JV Melo, Josy Reiffers, Françis Belloc	2002	7
20	Prognosis and prognostic factors for patients with chronic myeloid leukemia: Nontransplant therapy Seminars in Hematology ·Joerg Hasford, Markus Pfirrmann, R. Hehlmann, Michele Baccarani, François Guilhot, F-X Mahon, Hanneke C. Kluin‐Nelemans, K Ohnishi, J. Thaler, J. L. Steegmann	2003	5

About F-X Mahon

F-X Mahon is a scholar working on Hematology, Genetics, Rheumatology, Immunology and Immunology and Allergy, having authored 26 papers that have together received 682 indexed citations. Recurring topics across this work include Chronic Myeloid Leukemia Treatments (20 papers), Eosinophilic Disorders and Syndromes (10 papers), Chronic Lymphocytic Leukemia Research (9 papers), Mast cells and histamine (3 papers), Acute Myeloid Leukemia Research (3 papers), PI3K/AKT/mTOR signaling in cancer (3 papers), Cytokine Signaling Pathways and Interactions (2 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (2 papers). The work is most often cited by research in Hematology (496 citations), Genetics (370 citations), Rheumatology (230 citations), Immunology (74 citations) and Oncology (91 citations). F-X Mahon has collaborated with scholars based in France, United States and Germany. Frequent co-authors include Josy Reiffers, Françis Belloc, Jean Ripoche, Claude Preudhomme, JV Melo, Valérie Lagarde, Catherine Roche‐Lestienne, Christophe F. Grosset, Franck E. Nicolini and Philippe Rousselot. Their work appears in journals such as Leukemia, Blood, Annals of Oncology, British Journal of Haematology and Seminars in Hematology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact